Enveric Biosciences (ENVB) Stock Price, News & Analysis

Company Overview

Enveric Biosciences, Inc. is a biotechnology company focused on discovering and developing novel therapeutics for cancer and central nervous system disorders. The company’s research programs draw on cannabinoid- and psychedelic-inspired compounds intended to address unmet medical needs while potentially avoiding some of the limitations associated with naturally occurring compounds.

Enveric has developed a pipeline of investigational small-molecule drug candidates, including programs aimed at neuropsychiatric conditions such as depression and cancer-related complications. Its research platform has included the Psybrary library of novel psychedelic molecules, which was obtained through the company’s acquisition of Canadian biotechnology company MagicMed Industries. Enveric has also pursued oncology programs involving cannabinoid-derived compounds and treatments for symptoms associated with cancer and its therapies.

Headquartered in Naples, Florida, Enveric Biosciences conducts drug discovery and development activities for potential use in major international healthcare markets. Its candidates remain investigational and are subject to clinical and regulatory evaluation; the company does not currently market approved therapies based on these programs.

Key Stats

• Today's Range: $1.33 to $1.45
• 50-Day Range: $1.31 to $1.67
• 52-Week Range: $1.17 to $13.25
• Volume: 162,787 shs
• Average Volume: 1.38 million shs
• Market Capitalization: $6.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Enveric Biosciences Stock Analysis - MarketRank™

Enveric Biosciences scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Enveric Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Enveric Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Enveric Biosciences is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enveric Biosciences is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enveric Biosciences has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.35% of the float of Enveric Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Enveric Biosciences has a short interest ratio ("days to cover") of 0.19, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Enveric Biosciences has recently decreased by 32.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enveric Biosciences does not currently pay a dividend.

Dividend Growth

Enveric Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Enveric Biosciences has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Enveric Biosciences this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 3 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Enveric Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.41% of the stock of Enveric Biosciences is held by insiders.

Percentage Held by Institutions

13.82% of the stock of Enveric Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ENVB
• CIK: 890821
• Web: www.enveric.com
• Phone: (617) 444-8400
• Fax: 732-243-9254
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($12.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -168.04%
• Return on Assets: -145.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.21
• Quick Ratio: 10.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.00 per share
• Price / Book: 0.20

Miscellaneous

• Outstanding Shares: 4,480,000
• Free Float: 4,368,000
• Market Cap: $6.14 million
• Optionable: Not Optionable
• Beta: 1.18